BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 35941720)

  • 1. Xanthomatous Giant Cell Renal Cell Carcinoma: Another Morphologic Form of TSC -associated Renal Cell Carcinoma.
    Argani P; Matoso A; Pallavajjalla A; Haley L; Tseh-Lin M; Ng J; Chow CW; Lotan T; Mehra R
    Am J Surg Pathol; 2022 Nov; 46(11):1554-1561. PubMed ID: 35941720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinicopathologic and Molecular Characterization of Xanthomatous Giant Cell Renal Cell Carcinomas: Further Support for a Close Morphologic Spectrum to Eosinophilic Solid and Cystic Renal Cell Carcinomas.
    Xu Y; Zhang X; Xia Q; Zhou Y; Wang X; Fang R; Wang Y; Tong Q; Chen J; Shi J; Fu Y; Rao Q
    Am J Surg Pathol; 2024 Jun; 48(6):662-670. PubMed ID: 38595297
    [TBL] [Abstract][Full Text] [Related]  

  • 3. "Oncocytoid Renal Cell Carcinomas After Neuroblastoma" Represent TSC -mutated Eosinophilic Solid and Cystic Renal Cell Carcinomas : Association With Prior Childhood Malignancy and Multifocality With Therapeutic Implications.
    Argani P; Medeiros LJ; Matoso A; Baraban E; Lotan T; Pawel BR; McKenney JK; Mehra R; Falzarano SM; Pallavajjalla A; Lin MT; Patel S; Rawwas J; Bendel AE; Gagan J; Palsgrove DN
    Am J Surg Pathol; 2023 Dec; 47(12):1335-1348. PubMed ID: 37522346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TSC/MTOR-mutated eosinophilic renal tumors are a distinct entity that is CK7+/CK20-/vimentin-: a validation study.
    Tjota MY; Wanjari P; Segal J; Antic T
    Hum Pathol; 2021 Sep; 115():84-95. PubMed ID: 33352195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. "Renal Cell Carcinoma With Leiomyomatous Stroma" Harbor Somatic Mutations of TSC1, TSC2, MTOR, and/or ELOC (TCEB1): Clinicopathologic and Molecular Characterization of 18 Sporadic Tumors Supports a Distinct Entity.
    Shah RB; Stohr BA; Tu ZJ; Gao Y; Przybycin CG; Nguyen J; Cox RM; Rashid-Kolvear F; Weindel MD; Farkas DH; Trpkov K; McKenney JK
    Am J Surg Pathol; 2020 May; 44(5):571-581. PubMed ID: 31850909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eosinophilic Solid and Cystic (ESC) Renal Cell Carcinomas Harbor TSC Mutations: Molecular Analysis Supports an Expanding Clinicopathologic Spectrum.
    Palsgrove DN; Li Y; Pratilas CA; Lin MT; Pallavajjalla A; Gocke C; De Marzo AM; Matoso A; Netto GJ; Epstein JI; Argani P
    Am J Surg Pathol; 2018 Sep; 42(9):1166-1181. PubMed ID: 29975249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eosinophilic Renal Cell Tumors With a TSC and MTOR Gene Mutations Are Morphologically and Immunohistochemically Heterogenous: Clinicopathologic and Molecular Study.
    Tjota M; Chen H; Parilla M; Wanjari P; Segal J; Antic T
    Am J Surg Pathol; 2020 Jul; 44(7):943-954. PubMed ID: 32091432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Somatic Bi-allelic Loss of TSC Genes in Eosinophilic Solid and Cystic Renal Cell Carcinoma.
    Mehra R; Vats P; Cao X; Su F; Lee ND; Lonigro R; Premkumar K; Trpkov K; McKenney JK; Dhanasekaran SM; Chinnaiyan AM
    Eur Urol; 2018 Oct; 74(4):483-486. PubMed ID: 29941307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eosinophilic vacuolated tumor (EVT) of kidney demonstrates sporadic TSC/MTOR mutations: next-generation sequencing multi-institutional study of 19 cases.
    Farcaş M; Gatalica Z; Trpkov K; Swensen J; Zhou M; Alaghehbandan R; Williamson SR; Magi-Galluzzi C; Gill AJ; Tretiakova M; Lopez JI; Montiel DP; Sperga M; Comperat E; Brimo F; Yilmaz A; Siadat F; Sangoi A; Gao Y; Ptákova N; Kuthi L; Pivovarcikova K; Rogala J; Agaimy A; Hartmann A; Fraune C; Rychly B; Hurnik P; Durcansky D; Bonert M; Gakis G; Michal M; Hora M; Hes O
    Mod Pathol; 2022 Mar; 35(3):344-351. PubMed ID: 34521993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Somatic Mutations of TSC2 or MTOR Characterize a Morphologically Distinct Subset of Sporadic Renal Cell Carcinoma With Eosinophilic and Vacuolated Cytoplasm.
    Chen YB; Mirsadraei L; Jayakumaran G; Al-Ahmadie HA; Fine SW; Gopalan A; Sirintrapun SJ; Tickoo SK; Reuter VE
    Am J Surg Pathol; 2019 Jan; 43(1):121-131. PubMed ID: 30303819
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-grade oncocytic tumor of kidney harboring TSC/MTOR mutation: clinicopathologic, immunohistochemical and molecular characteristics support a distinct entity.
    Zhang HZ; Xia QY; Wang SY; Shi MJ; Wang SY
    Virchows Arch; 2022 May; 480(5):999-1008. PubMed ID: 35099634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concurrent Eosinophilic Solid and Cystic Renal Cell Carcinoma and Angiomyolipoma With Epithelial Cysts in the Setting of Tuberous Sclerosis Complex: A Rare Synchronous Occurrence of 2 Distinct Entities.
    Cho WC; Collins K; Mnayer L; Cartun RW; Earle JS
    Int J Surg Pathol; 2019 Oct; 27(7):804-811. PubMed ID: 31142207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TSC/MTOR mutated renal cell carcinoma with leiomyomatous stroma is a distinct entity: a comprehensive study of 12 cases.
    Tjota MY; Sharma A; Wanjari P; Fitzpatrick C; Segal J; Antic T
    Hum Pathol; 2023 Apr; 134():124-133. PubMed ID: 36592877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renal Cell Carcinoma Associated With TSC/MTOR Genomic Alterations: An Update on its Expanding Spectrum and an Approach to Clinicopathologic Work-up.
    Shah RB; Mehra R
    Adv Anat Pathol; 2024 Mar; 31(2):105-117. PubMed ID: 37899532
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GPNMB expression identifies TSC1/2/mTOR-associated and MiT family translocation-driven renal neoplasms.
    Salles DC; Asrani K; Woo J; Vidotto T; Liu HB; Vidal I; Matoso A; Netto GJ; Argani P; Lotan TL
    J Pathol; 2022 Jun; 257(2):158-171. PubMed ID: 35072947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TSC loss is a clonal event in eosinophilic solid and cystic renal cell carcinoma: a multiregional tumor sampling study.
    Munari E; Settanni G; Caliò A; Segala D; Lonardi S; Sandrini S; Vacca P; Tumino N; Marconi M; Brunelli M; Gobbo S; Netto GJ; Moretta L; Zamboni G; Martignoni G
    Mod Pathol; 2022 Mar; 35(3):376-385. PubMed ID: 33990704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TSC/MTOR -associated Eosinophilic Renal Tumors Exhibit a Heterogeneous Clinicopathologic Spectrum : A Targeted Next-generation Sequencing and Gene Expression Profiling Study.
    Xia QY; Wang XT; Zhao M; He HY; Fang R; Ye SB; Li R; Wang X; Zhang RS; Lu ZF; Ma HH; Wang ZY; Rao Q
    Am J Surg Pathol; 2022 Nov; 46(11):1562-1576. PubMed ID: 35980750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Positive GPNMB Immunostaining Differentiates Renal Cell Carcinoma With Fibromyomatous Stroma Associated With TSC1/2/MTOR Alterations From Others.
    Li H; Argani P; Halper-Stromberg E; Lotan TL; Merino MJ; Reuter VE; Matoso A
    Am J Surg Pathol; 2023 Nov; 47(11):1267-1273. PubMed ID: 37661807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sclerosing TSC1 mutated renal cell carcinoma: An unusual pattern mimicking MITF family translocation renal cell carcinoma.
    Williamson SR; Cardili L; Whiteley LJ; Sanchez J; Kis O
    Genes Chromosomes Cancer; 2020 Oct; 59(10):591-594. PubMed ID: 32418252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular characterization of chromophobe renal cell carcinoma reveals mTOR pathway alterations in patients with poor outcome.
    Roldan-Romero JM; Santos M; Lanillos J; Caleiras E; Anguera G; Maroto P; García-Donas J; de Velasco G; Martinez-Montes ÁM; Calsina B; Monteagudo M; Letón R; Leandro-García LJ; Montero-Conde C; Cascón A; Robledo M; Rodriguez-Antona C
    Mod Pathol; 2020 Dec; 33(12):2580-2590. PubMed ID: 32616874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.